Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. David Taggart,
Dr. Weintraub presented the potential value of registries, describing the ASCERT study of almost 190,000 patients undergoing PCI (almost 80% with DES) or CABG in patients aged over 65 years. The study (published in the NEJM 2012) reported 4.4% superior survival with CABG at 4 years. Findings persisted across 10 subsets of patients.
Dr. Farooq presented the importance of scoring systems to allow improved prediction of likely outcome in patients undergoing PCI or CABG. He described the SYNTAX II Study (Lancet 2013) in identifying 8 variables which enabled prediction of survival in patients undergoing PCI or CABG.
Dr. Girerd described the adverse impact of incomplete revascularisation on long term survival and especially in younger patients. Dr Kappetein presented the Freedom Trial in patients with diabetes where CABG had a 5.4% survival advantage at 5 years over PCI. Similar findings were observed in the subset of patients with diabetes in the SYNTAX Trial.
Dr. Taggart summarised the session emphasising (i) that previous RCTs of PCI versus CABG (with the exception of the SYNTAX Trial) had enrolled highly selected patients who were quite different from most CABG patients; (ii) that the survival advantage of CABG over PCI did not usually emerge until 3-5 years; (iii) the difference between appropriate and inappropriate complete revascularisation (during PCI and CABG). Finally, he emphasised the importance of interventions in individual patients being overseen by the heart team rather than by individual practitioners to ensure that patients were likely to receive the optimal intervention, whether by PCI or CABG.
Optimal revascularisation for patients with complex lesions or multivessel coronary artery disease